Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb(TM)) on brain injury after temporary focal cerebral ischemia in rats

Daniel J. Cole, John C. Drummond, Piyush M. Patel, Jeffrey C. Nary, Richard Lee Applegate

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Previous studies have shown that diaspirin cross-linked hemoglobin (DCLHb(TM), 10 g/dL) decreases cerebral ischemia and the resultant injury in a dose-dependent manner, requiring large volumes of DCLHb(TM) for maximum efficacy. We assessed the effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of DCLHb(TM) on cerebral infarction volume. immediately after middle cerebral artery occlusion, rats were randomized to one of the following groups: Control, hematocrit not manipulated; 10/Hb, hematocrit decreased to 30% with 10% DCLHb(TM) (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30% with 7.5% albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb(TM) (20%, oncotic pressure 129 mm Hg) as the 10/Hb group (half the volume); or 15/Alb, the same dose of albumin (15%, oncotic pressure 130 mm Hg) as the 7.5/Alb group (half the volume). After 90 min of ischemia, 72 h of reperfusion was allowed. Infarction volume (mm3, mean ± SD) was less in the DCLHb(TM) groups (10/Hb = 79 ± 17; 20/Hb = 51 ± 14) than the oncotically matched albumin groups (7.5/Alb = 124 ± 21; 15/Alb = 85 ± 18) and the Control group (135 ± 17) (P < 0.05). These data indicate that in this model of cerebral ischemia, DCLHb(TM) decreases ischemic brain injury more effectively than albumin, and that a hyperoncotic preparation of DCLHb(TM) is preferable.

Original languageEnglish (US)
Pages (from-to)342-347
Number of pages6
JournalAnesthesia and Analgesia
Volume83
Issue number2
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Brain Ischemia
Brain Injuries
Pressure
Hematocrit
Albumins
diaspirin-cross-linked hemoglobin
Control Groups
Middle Cerebral Artery Infarction
Cerebral Infarction
Infarction
Reperfusion
Research Design
Ischemia
Wounds and Injuries

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb(TM)) on brain injury after temporary focal cerebral ischemia in rats. / Cole, Daniel J.; Drummond, John C.; Patel, Piyush M.; Nary, Jeffrey C.; Applegate, Richard Lee.

In: Anesthesia and Analgesia, Vol. 83, No. 2, 1996, p. 342-347.

Research output: Contribution to journalArticle

@article{3b55f89a7f624363bc75d5e28e7bd925,
title = "Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb(TM)) on brain injury after temporary focal cerebral ischemia in rats",
abstract = "Previous studies have shown that diaspirin cross-linked hemoglobin (DCLHb(TM), 10 g/dL) decreases cerebral ischemia and the resultant injury in a dose-dependent manner, requiring large volumes of DCLHb(TM) for maximum efficacy. We assessed the effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of DCLHb(TM) on cerebral infarction volume. immediately after middle cerebral artery occlusion, rats were randomized to one of the following groups: Control, hematocrit not manipulated; 10/Hb, hematocrit decreased to 30{\%} with 10{\%} DCLHb(TM) (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30{\%} with 7.5{\%} albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb(TM) (20{\%}, oncotic pressure 129 mm Hg) as the 10/Hb group (half the volume); or 15/Alb, the same dose of albumin (15{\%}, oncotic pressure 130 mm Hg) as the 7.5/Alb group (half the volume). After 90 min of ischemia, 72 h of reperfusion was allowed. Infarction volume (mm3, mean ± SD) was less in the DCLHb(TM) groups (10/Hb = 79 ± 17; 20/Hb = 51 ± 14) than the oncotically matched albumin groups (7.5/Alb = 124 ± 21; 15/Alb = 85 ± 18) and the Control group (135 ± 17) (P < 0.05). These data indicate that in this model of cerebral ischemia, DCLHb(TM) decreases ischemic brain injury more effectively than albumin, and that a hyperoncotic preparation of DCLHb(TM) is preferable.",
author = "Cole, {Daniel J.} and Drummond, {John C.} and Patel, {Piyush M.} and Nary, {Jeffrey C.} and Applegate, {Richard Lee}",
year = "1996",
doi = "10.1097/00000539-199608000-00024",
language = "English (US)",
volume = "83",
pages = "342--347",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb(TM)) on brain injury after temporary focal cerebral ischemia in rats

AU - Cole, Daniel J.

AU - Drummond, John C.

AU - Patel, Piyush M.

AU - Nary, Jeffrey C.

AU - Applegate, Richard Lee

PY - 1996

Y1 - 1996

N2 - Previous studies have shown that diaspirin cross-linked hemoglobin (DCLHb(TM), 10 g/dL) decreases cerebral ischemia and the resultant injury in a dose-dependent manner, requiring large volumes of DCLHb(TM) for maximum efficacy. We assessed the effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of DCLHb(TM) on cerebral infarction volume. immediately after middle cerebral artery occlusion, rats were randomized to one of the following groups: Control, hematocrit not manipulated; 10/Hb, hematocrit decreased to 30% with 10% DCLHb(TM) (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30% with 7.5% albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb(TM) (20%, oncotic pressure 129 mm Hg) as the 10/Hb group (half the volume); or 15/Alb, the same dose of albumin (15%, oncotic pressure 130 mm Hg) as the 7.5/Alb group (half the volume). After 90 min of ischemia, 72 h of reperfusion was allowed. Infarction volume (mm3, mean ± SD) was less in the DCLHb(TM) groups (10/Hb = 79 ± 17; 20/Hb = 51 ± 14) than the oncotically matched albumin groups (7.5/Alb = 124 ± 21; 15/Alb = 85 ± 18) and the Control group (135 ± 17) (P < 0.05). These data indicate that in this model of cerebral ischemia, DCLHb(TM) decreases ischemic brain injury more effectively than albumin, and that a hyperoncotic preparation of DCLHb(TM) is preferable.

AB - Previous studies have shown that diaspirin cross-linked hemoglobin (DCLHb(TM), 10 g/dL) decreases cerebral ischemia and the resultant injury in a dose-dependent manner, requiring large volumes of DCLHb(TM) for maximum efficacy. We assessed the effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of DCLHb(TM) on cerebral infarction volume. immediately after middle cerebral artery occlusion, rats were randomized to one of the following groups: Control, hematocrit not manipulated; 10/Hb, hematocrit decreased to 30% with 10% DCLHb(TM) (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30% with 7.5% albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb(TM) (20%, oncotic pressure 129 mm Hg) as the 10/Hb group (half the volume); or 15/Alb, the same dose of albumin (15%, oncotic pressure 130 mm Hg) as the 7.5/Alb group (half the volume). After 90 min of ischemia, 72 h of reperfusion was allowed. Infarction volume (mm3, mean ± SD) was less in the DCLHb(TM) groups (10/Hb = 79 ± 17; 20/Hb = 51 ± 14) than the oncotically matched albumin groups (7.5/Alb = 124 ± 21; 15/Alb = 85 ± 18) and the Control group (135 ± 17) (P < 0.05). These data indicate that in this model of cerebral ischemia, DCLHb(TM) decreases ischemic brain injury more effectively than albumin, and that a hyperoncotic preparation of DCLHb(TM) is preferable.

UR - http://www.scopus.com/inward/record.url?scp=0030036991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030036991&partnerID=8YFLogxK

U2 - 10.1097/00000539-199608000-00024

DO - 10.1097/00000539-199608000-00024

M3 - Article

C2 - 8694316

AN - SCOPUS:0030036991

VL - 83

SP - 342

EP - 347

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 2

ER -